Macrogenics

Filed a patent for "bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof" on Thu, July 11, 2024

Filed a patent for "pharmaceutical compositions of a b7-h3 antibody and use of the same" on Tue, January 9, 2024

Filed a patent for "methods for the use of a b7-h3 antibody-drug conjugate alone or in combination" on Thu, July 20, 2023

Filed a patent for "use of bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies" on Thu, July 13, 2023

Filed a patent for "b7-h3 directed antibody drug conjugates" on Thu, August 31, 2023

Filed a patent for "methods for the use of a pd-1 x ctla-4 bispecific molecule" on Thu, October 5, 2023

Filed a patent for "covalent diabodies and uses thereof" on Thu, November 30, 2023

Filed a patent for "bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof" on Thu, December 14, 2023

Filed a patent for "tri-specific binding molecules that specifically bind to multiple cancer antigens" on Thu, April 11, 2024

Filed a patent for "variant cd3-binding domains and their use in combination therapies for the treatment of disease" on Thu, February 8, 2024

Filed a patent for "methods for the treatment of disease using immunoglobulins having fc regions altered affinities for fcyractivating and fcyrinhibiting" on Thu, January 18, 2024

Filed a patent for "multl-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens" on Thu, June 6, 2024

Filed a patent for "methods of using bispecific molecules having immunoreactivity with pd-1 and ctla-4" on Thu, March 14, 2024

Filed a patent for "lag-3-binding molecules and methods of use thereof" on Thu, April 18, 2024

Filed a patent for "her2/neu-specific antibodies and methods of using same" on Thu, April 25, 2024

Filed a patent for "bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof" on Thu, November 24, 2022

Filed a patent for "therapy for the treatment of cancer" on Thu, February 23, 2023

Filed a patent for "pharmaceutical compositions of a pd-1 antibody and use of the same" on Thu, January 26, 2023

Filed a patent for "bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof" on Thu, June 1, 2023

Filed a patent for "bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof" on Thu, December 22, 2022

Filed a patent for "cd137 binding molecules and uses thereof" on Thu, March 30, 2023

Filed a patent for "pharmaceutical compositions of a her2/neu antibody and use of the same" on Thu, February 23, 2023